An Investigator-initiated Phase I Study of SELINEXOR in Combination With Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
Latest Information Update: 20 Oct 2022
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Selinexor (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 13 Oct 2022 Status changed from active, no longer recruiting to discontinued.
- 11 Oct 2022 Planned primary completion date changed from 1 Oct 2024 to 1 Oct 2023.
- 11 Oct 2022 Status changed from recruiting to active, no longer recruiting.